Hosna Mirfakhraee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hosna Mirfakhraee has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Maryam Niksolat
Department of Geriatric Medicine, Geriatric Mental Health Research Center, Firoozabadi Clinical Research Development Unit (FACRDU), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 shared publications - Samaneh Saghafian Larijani
Department of Obstetrics and Gynecology, Firoozabadi Clinical Research Development Unit, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 shared publications - Zhale Zandieh
Department of Ageing, Assistant Professor of Geriatric Medicine, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
2 shared publications - Adnan Tizmaghz
Breast Cancer Research Center, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Ali Tayebi
Department of General Surgery, Firoozabadi Clinical and Research Development Unit, Iran University Medical Sciences, Tehran, Iran
1 shared publication- Ali Tayebi
Firoozabadi Clinical Research Development Unit (F A CRD U) Iran University of Medical Sciences (IUMS), Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 9 August 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13, e13297
Adverse side effects of maternal levothyroxine consumption in pregnant women with subclinical hypothyroidism: a systematic review study
Introduction: Subclinical hypothyroidism (SCH) during pregnancy is a prevalent endocrine disorder, often managed with levothyroxine therapy. Although levothyroxine (LT4) is widely prescribed to mitigate potential risks associated with SCH, concerns persist regarding its safety profile and possible adverse effects on pregnancy outcomes. This systematic review evaluates the current evidence on the adverse maternal, fetal, and neonatal outcomes linked to levothyroxine use in pregnant women diagnosed with SCH. Materials and Methods: This systematic review was conducted on original research studies published between 2015 and 2025 that evaluated the adverse effects of levothyroxine use in pregnant women with SCH. Comprehensive searches were performed across PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Google Scholar. Data extraction was independently performed by two reviewers using a standardized checklist, with a third reviewer resolving any discrepancies. Results: The systematic review encompassed 12 studies totaling 1,952,592 participants (20,010 treated with LT4; 1,932,582 untreated). Preterm labor was the most frequent adverse outcome (reported in six studies), followed by gestational diabetes (three studies). Small-for-gestational-age (SGA) infants, low birth weight (LBW), and preeclampsia each appeared in two studies. Other effects, seizures in children, inadequate gestational weight gain, infant death, premature rupture of membranes, fetal macrosomia, and postpartum hemorrhage, were each noted once. Two studies found no adverse effects. Conclusion: This review study highlights preterm labor as the most common adverse outcome of LT4 use in pregnancy, followed by gestational diabetes. Repeated observations of SGA infants, LBW, and preeclampsia further highlight risks to fetal growth and maternal health. Less common but serious complications, such as seizures, inadequate weight gain, infant death, premature membrane rupture, fetal macrosomia, and postpartum hemorrhage, were each noted once, while two studies found no adverse effects, indicating that risk may depend on study factors, patient populations. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251105434) and Research Registry (UIN: reviewregistry2025) websites.
- 9 August 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13, e13297
Open AccessAdverse side effects of maternal levothyroxine consumption in pregnant women with subclinical hypothyroidism: a systematic review study
Introduction: Subclinical hypothyroidism (SCH) during pregnancy is a prevalent endocrine disorder, often managed with levothyroxine therapy. Although levothyroxine (LT4) is widely prescribed to mitigate potential risks associated with SCH, concerns persist regarding its safety profile and possible adverse effects on pregnancy outcomes. This systematic review evaluates the current evidence on the adverse maternal, fetal, and neonatal outcomes linked to levothyroxine use in pregnant women diagnosed with SCH. Materials and Methods: This systematic review was conducted on original research studies published between 2015 and 2025 that evaluated the adverse effects of levothyroxine use in pregnant women with SCH. Comprehensive searches were performed across PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Google Scholar. Data extraction was independently performed by two reviewers using a standardized checklist, with a third reviewer resolving any discrepancies. Results: The systematic review encompassed 12 studies totaling 1,952,592 participants (20,010 treated with LT4; 1,932,582 untreated). Preterm labor was the most frequent adverse outcome (reported in six studies), followed by gestational diabetes (three studies). Small-for-gestational-age (SGA) infants, low birth weight (LBW), and preeclampsia each appeared in two studies. Other effects, seizures in children, inadequate gestational weight gain, infant death, premature rupture of membranes, fetal macrosomia, and postpartum hemorrhage, were each noted once. Two studies found no adverse effects. Conclusion: This review study highlights preterm labor as the most common adverse outcome of LT4 use in pregnancy, followed by gestational diabetes. Repeated observations of SGA infants, LBW, and preeclampsia further highlight risks to fetal growth and maternal health. Less common but serious complications, such as seizures, inadequate weight gain, infant death, premature membrane rupture, fetal macrosomia, and postpartum hemorrhage, were each noted once, while two studies found no adverse effects, indicating that risk may depend on study factors, patient populations. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251105434) and Research Registry (UIN: reviewregistry2025) websites.
- Open Access
- 1 December 2022
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 11 (12) , 7543-7548
The impact of socially accountable health professional education: Systematic review
Medical education is socially responsible for a global educational movement that transforms the development and presentation of medical schools in higher education. Therefore, in the present systematic review, we aimed to evaluate the impact of socially accountable health professional education. Published research articles were reviewed by searching the relevant terms invalid databases. In the initial search, 2340 records were obtained. At this stage, 1482 records were deleted due to duplication, and 773 records were removed due to indirect connection with the subject. Then, 85 articles were retrieved for full-text review. Finally, the complete review led to the selection of nine studies that met all inclusion criteria. Based on the results of the present systematic review, among the nine reviewed articles, four studies (44.44%) evaluated the effectiveness of social accountability on increasing the sense of empowerment, self-confidence, competencies such as teamwork, communication skills, and readiness for work. Three studies (33.333%) assessed the effectiveness of social accountability on providing further and better medical services and reducing infant mortality. Also, in two articles (22.22%), students’ lack of knowledge about social accountability was studied. Social accountability can help cultivate a healthy and skilled medical workforce and be effective in improving health services provided to the people. On the other hand, there are different perceptions and views on what social responsibility really is and how its effectiveness can be measured. Also, it is highly important to provide awareness in this regard for students.
- 1 December 2022
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 11 (12) , 7543-7548
Open AccessThe impact of socially accountable health professional education: Systematic review
Medical education is socially responsible for a global educational movement that transforms the development and presentation of medical schools in higher education. Therefore, in the present systematic review, we aimed to evaluate the impact of socially accountable health professional education. Published research articles were reviewed by searching the relevant terms invalid databases. In the initial search, 2340 records were obtained. At this stage, 1482 records were deleted due to duplication, and 773 records were removed due to indirect connection with the subject. Then, 85 articles were retrieved for full-text review. Finally, the complete review led to the selection of nine studies that met all inclusion criteria. Based on the results of the present systematic review, among the nine reviewed articles, four studies (44.44%) evaluated the effectiveness of social accountability on increasing the sense of empowerment, self-confidence, competencies such as teamwork, communication skills, and readiness for work. Three studies (33.333%) assessed the effectiveness of social accountability on providing further and better medical services and reducing infant mortality. Also, in two articles (22.22%), students’ lack of knowledge about social accountability was studied. Social accountability can help cultivate a healthy and skilled medical workforce and be effective in improving health services provided to the people. On the other hand, there are different perceptions and views on what social responsibility really is and how its effectiveness can be measured. Also, it is highly important to provide awareness in this regard for students.
- Open Access
- 2 January 2022
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 12 (1)
Renal vein thrombosis in a recent COVID-19 patient; a case report
We report a 74-year-old male with a recent history of COVID-19 pneumonia who was admitted with acute periumbilical and left lower quadrant pain and respiratory distress. Laboratory data showed pre-renal azotemia and microscopic hematuria. An abdominopelvic computerized tomography (CT) scan with intravenous contrast was conducted, showing signs of right renal vein thrombosis (RVT) with extension to inferior vena cava (IVC), without any evidence of renal ischemia. The patient did not have any risk factors for thrombosis except for probable hypercoagulopathy due to COVID-19 and diabetes mellitus. He was not an appropriate candidate for surgical or radiologic thrombectomy, thus received heparin infusion accordingly. Unfortunately, he died after the cardiopulmonary arrest on the second day of admission. Considering his respiratory distress, we suspect pulmonary embolism as the most probable cause of death.
- 2 January 2022
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 12 (1)
Open AccessRenal vein thrombosis in a recent COVID-19 patient; a case report
We report a 74-year-old male with a recent history of COVID-19 pneumonia who was admitted with acute periumbilical and left lower quadrant pain and respiratory distress. Laboratory data showed pre-renal azotemia and microscopic hematuria. An abdominopelvic computerized tomography (CT) scan with intravenous contrast was conducted, showing signs of right renal vein thrombosis (RVT) with extension to inferior vena cava (IVC), without any evidence of renal ischemia. The patient did not have any risk factors for thrombosis except for probable hypercoagulopathy due to COVID-19 and diabetes mellitus. He was not an appropriate candidate for surgical or radiologic thrombectomy, thus received heparin infusion accordingly. Unfortunately, he died after the cardiopulmonary arrest on the second day of admission. Considering his respiratory distress, we suspect pulmonary embolism as the most probable cause of death.
- 4 October 2021
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1)
Evaluation of the relationship between preeclampsia and positive rectovaginal culture of group B Streptococcus and Helicobacter pylori positive serology
Introduction: Identifying the incidence of pathogen colonizations in pregnant women with preeclampsia can be effective in providing proper treatment and reducing complications. Objectives: We evaluated the frequency and association between positive rectovaginal culture of group B Streptococcus (GBS) and positive Helicobacter pylori serology with preeclampsia in two groups of pregnant women (with and without preeclampsia). Patients and Methods: The present case-control study included pregnant women with preeclampsia and healthy pregnant controls during 2019-2020. Blood and rectovaginal samples were obtained and the data were statistically analyzed using SPSS software. Results: Fifty-four people were included in the study. The mean gestational age was 36 ± 3.4 months in the preeclampsia group and 37 ± 2.9 months in the control group. There was no significant relationship between preeclampsia and H. pylori-positive serology (P=0.84). Additionally, the association between positive H. pylori serology and the severity of preeclampsia was not significant (P=0.15). However, there was a significant relationship between positive H. pylori tests with early- and late-onset preeclampsia (P=0.04). However, there was no statistically significant relationship between the positive rectovaginal culture of GBS and preeclampsia, the severity of preeclampsia, the onset time, or the weight of newborns. Conclusion: There was a significant relationship between H. pylori infection and late-onset preeclampsia in preeclamptic mothers. H. pylori screening and eradication therapy before pregnancy can prevent preeclampsia and its serious consequences in both the mother and the fetus.
- 4 October 2021
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1)
Evaluation of the relationship between preeclampsia and positive rectovaginal culture of group B Streptococcus and Helicobacter pylori positive serology
Introduction: Identifying the incidence of pathogen colonizations in pregnant women with preeclampsia can be effective in providing proper treatment and reducing complications. Objectives: We evaluated the frequency and association between positive rectovaginal culture of group B Streptococcus (GBS) and positive Helicobacter pylori serology with preeclampsia in two groups of pregnant women (with and without preeclampsia). Patients and Methods: The present case-control study included pregnant women with preeclampsia and healthy pregnant controls during 2019-2020. Blood and rectovaginal samples were obtained and the data were statistically analyzed using SPSS software. Results: Fifty-four people were included in the study. The mean gestational age was 36 ± 3.4 months in the preeclampsia group and 37 ± 2.9 months in the control group. There was no significant relationship between preeclampsia and H. pylori-positive serology (P=0.84). Additionally, the association between positive H. pylori serology and the severity of preeclampsia was not significant (P=0.15). However, there was a significant relationship between positive H. pylori tests with early- and late-onset preeclampsia (P=0.04). However, there was no statistically significant relationship between the positive rectovaginal culture of GBS and preeclampsia, the severity of preeclampsia, the onset time, or the weight of newborns. Conclusion: There was a significant relationship between H. pylori infection and late-onset preeclampsia in preeclamptic mothers. H. pylori screening and eradication therapy before pregnancy can prevent preeclampsia and its serious consequences in both the mother and the fetus.
- Open Access
- 1 July 2020
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 5 (2) , e25
The changes in therapeutic and managerial protocols for patients suffering ST-segment elevation myocardial infarction in COVID-19 pandemic; a systematic review and meta-analysis
Introduction: Apart from the direct effect of COVID-19 on the incidence of ischemic heart disease, the pandemic effect of this infection on the control of ischemic heart disease and on the clinical consequences of these patients and also their hospital admission is also significant. Objectives: The present review attempted to assess the admission rate, treatment protocols, and outcome changes in patients suffering ST-segment elevation myocardial infarction (STEMI) in the COVID-19 outbreak. Materials and Methods: The included studies were identified through electronically reviewing the manuscripts databases of MEDLINE, EMBASE, Web of knowledge, and Google Scholar from inception to September 2020. The titles and abstracts of the manuscripts were screened by two blinded reviewers followed by an in-depth assessment of the full texts for assigning the inclusion appropriateness. Results: Eighteen articles (including 6225 STEMI patients hospitalized within the COVID-19 pandemic duration and 55711 STEMI patients in pre-COVID-19 periods) were desirable for the final analysis. A longer delay among symptom onset and first medical contact (FMC) in the COVID-19 lockdown period than before the COVID-19 pandemic was revealed. Comparing STEMI-related death in the COVID-19 period compared to the pre-COVID-19 duration showed a significantly higher death rate and a higher rate of thrombolytic therapy. The examined pre-COVID-19 and COVID-19 periods showed a reduction in STEMI patients’ admissions reached 30.9%. Additionally, entering the COVID-19 period resulted in a significant 44.4% reduction in the number of primary percutaneous coronary intervention. Conclusion: During the COVID-19 pandemic, the management of STEMI has undergone significant changes, including reduced hospital admissions, reduced invasive and semi-invasive treatment interventions, increased STEMI-related mortality, increased thrombolytic therapy, and delayed patients’ referral to the hospitals.
- 1 July 2020
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 5 (2) , e25
Open AccessThe changes in therapeutic and managerial protocols for patients suffering ST-segment elevation myocardial infarction in COVID-19 pandemic; a systematic review and meta-analysis
Introduction: Apart from the direct effect of COVID-19 on the incidence of ischemic heart disease, the pandemic effect of this infection on the control of ischemic heart disease and on the clinical consequences of these patients and also their hospital admission is also significant. Objectives: The present review attempted to assess the admission rate, treatment protocols, and outcome changes in patients suffering ST-segment elevation myocardial infarction (STEMI) in the COVID-19 outbreak. Materials and Methods: The included studies were identified through electronically reviewing the manuscripts databases of MEDLINE, EMBASE, Web of knowledge, and Google Scholar from inception to September 2020. The titles and abstracts of the manuscripts were screened by two blinded reviewers followed by an in-depth assessment of the full texts for assigning the inclusion appropriateness. Results: Eighteen articles (including 6225 STEMI patients hospitalized within the COVID-19 pandemic duration and 55711 STEMI patients in pre-COVID-19 periods) were desirable for the final analysis. A longer delay among symptom onset and first medical contact (FMC) in the COVID-19 lockdown period than before the COVID-19 pandemic was revealed. Comparing STEMI-related death in the COVID-19 period compared to the pre-COVID-19 duration showed a significantly higher death rate and a higher rate of thrombolytic therapy. The examined pre-COVID-19 and COVID-19 periods showed a reduction in STEMI patients’ admissions reached 30.9%. Additionally, entering the COVID-19 period resulted in a significant 44.4% reduction in the number of primary percutaneous coronary intervention. Conclusion: During the COVID-19 pandemic, the management of STEMI has undergone significant changes, including reduced hospital admissions, reduced invasive and semi-invasive treatment interventions, increased STEMI-related mortality, increased thrombolytic therapy, and delayed patients’ referral to the hospitals.